{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:44:18Z","timestamp":1787161458164,"version":"build-2736575974"},"reference-count":21,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,5,31]]},"abstract":"<jats:p>Congenital factor XIII (FXIII) deficiency is a rare, autosomal-recessive disorder, with most patients having an A-subunit (FXIII-A) deficiency. Patients experience life-threatening bleeds, impaired wound healing, and spontaneous abortions. In many countries, only plasma or cryoprecipitate treatments are available, but these carry a risk for allergic reactions and infection with blood-borne pathogens. The present study was a multinational, open-label, single-arm, phase 3 prophylaxis trial evaluating the efficacy and safety of a novel recombinant FXIII (rFXIII) in congenital FXIII-A subunit deficiency. Forty-one patients \u2265 6 years of age (mean, 26.4; range, 7-60) with congenital FXIII-A subunit deficiency were enrolled. Throughout the rFXIII prophylaxis, only 5 bleeding episodes (all trauma induced) in 4 patients were treated with FXIII-containing products. The crude mean bleeding rate was significantly lower than the historic bleeding rate (0.138 vs 2.91 bleeds\/patient\/year, respectively) for on-demand treatment. Transient, non-neutralizing, low-titer anti-rFXIII Abs developed in 4 patients, none of whom experienced allergic reactions, any bleeds requiring treatment, or changes in FXIII pharmacokinetics during the trial or follow-up. These non-neutralizing Abs declined below detection limits in all 4 patients despite further exposure to rFXIII or other FXIII-containing products. We conclude that rFXIII is safe and effective in preventing bleeding episodes in patients with congenital FXIII-A subunit deficiency. This study is registered at http:\/\/www..clinicaltrials.gov as number NCT00713648.<\/jats:p>","DOI":"10.1182\/blood-2011-10-386045","type":"journal-article","created":{"date-parts":[[2012,3,26]],"date-time":"2012-03-26T23:34:06Z","timestamp":1332804846000},"page":"5111-5117","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":103,"title":["Recombinant factor XIII: a safe and novel treatment for congenital factor XIII deficiency"],"prefix":"10.1182","volume":"119","author":[{"given":"Aida","family":"Inbal","sequence":"first","affiliation":[{"name":"Thrombosis and Hemostasis Unit, Rabin Medical Center, Petah Tikva and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Oldenburg","sequence":"additional","affiliation":[{"name":"Institute of Experimental Haematology and Transfusion Medicine, University Clinic, Bonn, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Carcao","sequence":"additional","affiliation":[{"name":"Haematology\/Oncology, Hospital for Sick Children, Toronto, ON;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Rosholm","sequence":"additional","affiliation":[{"name":"Biostatistics, Novo Nordisk A\/S, Copenhagen, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramin","family":"Tehranchi","sequence":"additional","affiliation":[{"name":"Medical and Science, Haemostasis R&D Portfolio, Novo Nordisk A\/S, Copenhagen, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Nugent","sequence":"additional","affiliation":[{"name":"Department of Hematology, Children's Hospital of Orange County\/University of California, Irvine Medical School, Orange, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"4","key":"2019111815035596300_B1","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1055\/s-0029-1225765","article-title":"Factor XIII deficiency.","volume":"35","author":"Karimi","year":"2009","journal-title":"Semin Thromb Hemost"},{"issue":"6","key":"2019111815035596300_B2","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1160\/TH07-01-0034","article-title":"International registry on factor XIII deficiency: a basis formed mostly on European data.","volume":"97","author":"Study Group","year":"2007","journal-title":"Thromb Haemost"},{"issue":"3","key":"2019111815035596300_B3","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1046\/j.1365-2516.2002.00633.x","article-title":"Rare coagulation deficiencies.","volume":"8","author":"Peyvandi","year":"2002","journal-title":"Haemophilia"},{"issue":"5","key":"2019111815035596300_B4","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.blre.2011.03.001","article-title":"An update of the mutation profile of Factor 13 A and B genes.","volume":"25","author":"Biswas","year":"2011","journal-title":"Blood Rev"},{"issue":"6","key":"2019111815035596300_B5","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/00062752-199811000-00003","article-title":"Factor concentrates for the treatment of factor XIII deficiency.","volume":"5","author":"Gootenberg","year":"1998","journal-title":"Curr Opin Hematol"},{"issue":"3","key":"2019111815035596300_B6","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1046\/j.1365-2141.1999.01648.x","article-title":"Factor XIII deficiency.","volume":"107","author":"Anwar","year":"1999","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111815035596300_B7","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1182\/blood-2005-02-0788","article-title":"Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency.","volume":"108","author":"Lovejoy","year":"2006","journal-title":"Blood"},{"issue":"7","key":"2019111815035596300_B8","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1111\/j.1538-7836.2011.04315.x","article-title":"Subcommittee of the ISTH. Diagnosis and classification of factor XIII deficiencies.","volume":"9","author":"on behalf of the Factor XIII and Fibrinogen SSC","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"11","key":"2019111815035596300_B9","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1111\/j.1538-7836.2010.04028.x","article-title":"Factor XIII\u2013an under diagnosed deficiency\u2013are we using the right assays?","volume":"8","author":"Lawrie","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"12","key":"2019111815035596300_B10","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1046\/j.1538-7836.2003.00469.x","article-title":"UK NEQAS. Problems relating to the laboratory diagnosis of factor XIII deficiency: a UK NEQAS study.","volume":"1","author":"Jennings","year":"2003","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2019111815035596300_B11","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1055\/s-0038-1649787","article-title":"Pharmacokinetics and tolerability of factor XIII concentrates prepared from human placenta or plasma: a crossover randomised study.","volume":"74","author":"Brackmann","year":"1995","journal-title":"Thromb Haemost"},{"issue":"2","key":"2019111815035596300_B12","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/j.1365-2516.2009.02123.x","article-title":"Prophylactic therapy with Fibrogammin P is associated with a decreased incidence of bleeding episodes: a retrospective study.","volume":"16","author":"Lusher","year":"2010","journal-title":"Haemophilia"},{"issue":"4","key":"2019111815035596300_B13","first-page":"173","article-title":"Efficiency of intermittent prophylactic factor XIII substitution in congenital factor XIII A subunit deficiency.","volume":"42","author":"Yoshida","year":"1996","journal-title":"Japanese Journal of Transfusion Medicine"},{"issue":"6","key":"2019111815035596300_B14","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1111\/j.1538-7836.2011.04281.x","article-title":"Successful long-term replacement therapy with FXIII concentrate (Fibrogammin P) for severe congenital factor XIII deficiency: a prospective multicentre study.","volume":"9","author":"Groupe d'Etudes Francophone du FXIII","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2019111815035596300_B15","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1365-2516.2010.02420.x","article-title":"Influence of the type of F8 gene mutation on inhibitor development in a single centre cohort of severe haemophilia A patients.","volume":"17","author":"Gouw","year":"2011","journal-title":"Haemophilia"},{"issue":"2","key":"2019111815035596300_B16","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1365-2516.2010.02422.x","article-title":"Paediatric Working Party of UKHCDO. Treatment related factors and inhibitor development in children with severe haemophilia A.","volume":"17","author":"Maclean","year":"2011","journal-title":"Haemophilia"},{"issue":"2","key":"2019111815035596300_B17","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1538-7836.2003.t01-1-00553.x","article-title":"North American Rare Bleeding Disorder Study Group. Rare Bleeding Disorder Registry: deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias.","volume":"2","author":"Acharya","year":"2004","journal-title":"J Thromb Haemost"},{"issue":"6","key":"2019111815035596300_B18","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1046\/j.1351-8216.2003.00814.x","article-title":"Immunoadsorption for coagulation factor inhibitors: a retrospective critical appraisal of 10 consecutive cases from a single institution.","volume":"9","author":"Rivard","year":"2003","journal-title":"Haemophilia"},{"issue":"2","key":"2019111815035596300_B19","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1365-2141.1992.tb06438.x","article-title":"A reversed activity staining procedure for detection of an acquired antibody against factor XIII in a girl with factor XIII deficiency.","volume":"82","author":"Seiving","year":"1992","journal-title":"Br J Haematol"},{"issue":"12","key":"2019111815035596300_B20","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1046\/j.1538-7836.2003.00477.x","article-title":"Low detection rate of antibodies to nonfunctional epitopes on factor VIII in patients with hemophilia A and negative for inhibitors by Bethesda assay.","volume":"1","author":"Ling","year":"2003","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2019111815035596300_B21","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s002770050179","article-title":"Antibodies to factor VIII in plasma of patients with hemophilia A and normal subjects.","volume":"72","author":"Batlle","year":"1996","journal-title":"Ann Hematol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/22\/5111\/1491790\/zh802212005111.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/22\/5111\/1491790\/zh802212005111.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T15:04:18Z","timestamp":1574089458000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/119\/22\/5111\/105460\/Recombinant-factor-XIII-a-safe-and-novel-treatment"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,31]]},"references-count":21,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2012,5,31]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-10-386045","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,31]]}}}